Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Mult Scler Relat Disord ; 41: 102016, 2020 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-32135497

RESUMO

BACKGROUND: Factors associated with adherence to disease modifying therapies (DMT) in patients with Multiple Sclerosis (MS) have been reported before, but little has been studied on compliance to a physician's initial treatment recommendations. The objective of this study was to assess the factors associated with compliance to physician recommended treatment in treatment-naïve patients with MS. METHODS: We studied a cohort of patients with MS followed at an academic MS center in Toronto, Canada between January 2015 and May 2018. We used log-binomial models to identify patient-level factors (age, sex, and smoking history), and MS-specific clinical details (delay in diagnosis, and age at diagnosis) associated with compliance. RESULTS: Of the 332 patients, 256 (77.1%) were recommended DMT and 80 (31.3%) did not follow the recommendation. The most common causes for refusal to initiate DMT were: personal preference to not embark on a medication (46.2%), wishing to use a conservative approach (22.5%) or use of complementary medical approaches (18.8%). Twenty-one () patients who initially were compliant to treatment recommendations subsequently stopped DMT against medical advice. The two most common reasons for this nonadherence included adverse effects (61.8%) and personal preference (19.0%). Every year delay in the diagnosis of MS was associated with a lower risk of compliance (risk ratio 0.97, 95% CI, 0.94-1.00). CONCLUSION: Non-compliance to DMT recommendation in patients with MS in a Canadian practice is sizable, due to patients' own perspectives of disease and their belief in alternative complementary medicine.


Assuntos
Fatores Imunológicos/administração & dosagem , Adesão à Medicação , Esclerose Múltipla/tratamento farmacológico , Adulto , Canadá , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Esclerose Múltipla Recidivante-Remitente/tratamento farmacológico , Pesquisa Qualitativa , Fatores de Risco
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA